GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » YSB Inc (HKSE:09885) » Definitions » Debt-to-EBITDA

YSB (HKSE:09885) Debt-to-EBITDA : 5.95 (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is YSB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

YSB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$105 Mil. YSB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$126 Mil. YSB's annualized EBITDA for the quarter that ended in Jun. 2024 was HK$39 Mil. YSB's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was 5.95.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for YSB's Debt-to-EBITDA or its related term are showing as below:

HKSE:09885' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -23.79   Med: -0.3   Max: -0.07
Current: -23.79

During the past 4 years, the highest Debt-to-EBITDA Ratio of YSB was -0.07. The lowest was -23.79. And the median was -0.30.

HKSE:09885's Debt-to-EBITDA is ranked worse than
100% of 444 companies
in the Healthcare Providers & Services industry
Industry Median: 2.405 vs HKSE:09885: -23.79

YSB Debt-to-EBITDA Historical Data

The historical data trend for YSB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

YSB Debt-to-EBITDA Chart

YSB Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
-0.52 -0.46 -0.13 -0.07

YSB Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-EBITDA Get a 7-Day Free Trial - -0.11 -0.03 -3.95 5.95

Competitive Comparison of YSB's Debt-to-EBITDA

For the Pharmaceutical Retailers subindustry, YSB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


YSB's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, YSB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where YSB's Debt-to-EBITDA falls into.



YSB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

YSB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(131.317 + 98.006) / -3353.63
=-0.07

YSB's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(104.739 + 125.763) / 38.734
=5.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2024) EBITDA data.


YSB  (HKSE:09885) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


YSB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of YSB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


YSB Business Description

Traded in Other Exchanges
N/A
Address
No. 8 Brand Street, No. 397 Xingang Middle Road, Yaoshibang Building, TIT Creative Industry Zone, Guangzhou, CHN
YSB Inc is a digital pharmaceutical platform serving businesses outside of hospitals in China. The Company is committed to using digitalization to empower participants in the out-of-hospital pharmaceutical market, including pharmaceutical companies, distributors, vendors, pharmacies and primary healthcare institutions, and strives to bring pharmaceutical health products and services to the downstream safely and efficiently, so that users can easily obtain a large number of comprehensive and high-quality drugs at a fair and transparent price. It has turned the process of pharmaceutical transaction and service into a digitalized, standardized and scalable one.
Executives
Chu Mang Yee 2201 Interest of corporation controlled by you
Meta Group Limited 2201 Interest of corporation controlled by you
Sounda Properties Limited 2201 Interest of corporation controlled by you
Shenzhen Songhe International Capital Management Partnership (limited Partnership) 2201 Interest of corporation controlled by you
Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. 2101 Beneficial owner
Shanghai Fosun Pharmaceutical (group) Co., Ltd. 2201 Interest of corporation controlled by you
Shanghai Fosun High Technology (group) Co., Ltd. 2201 Interest of corporation controlled by you
Chen Xiaohong 2201 Interest of corporation controlled by you
H Capital V Gp, L.p. 2201 Interest of corporation controlled by you
H Capital V Gp, Ltd. 2201 Interest of corporation controlled by you
Guo Guangchang 2201 Interest of corporation controlled by you
Fosun Holdings Limited 2201 Interest of corporation controlled by you
Fosun International Holdings Ltd. 2201 Interest of corporation controlled by you
Fosun International Limited 2201 Interest of corporation controlled by you
Miyt Holdings Limited 2101 Beneficial owner

YSB Headlines

No Headlines